( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group.
OBJECTIVE To compare intranasal nafarelin and intramuscular leuprolide acetate ( LA ) depot in the management of  endometriosis .  STUDY DESIGN A multicenter , prospect i ve , r and omized , double-placebo , double-blind study was conducted on subjects who had symptoms and signs of endometriosis and bone mineral density ( BMD ) within the age-appropriate normal range . For 6 months , 99 subjects received nafarelin , 200 micrograms twice daily , and placebo injections once monthly ; 93 subjects received LA depot injections , 3.75 mg once monthly , and placebo nasal spray , twice daily . Subjects were followed throughout treatment and for six months after treatment . The main outcome measures were changes in endometriosis symptoms and signs , BMD measurements , subject-reported and objective ly measured hot flushes and circulating estradiol concentrations . RESULTS Nafarelin was as effective as LA depot in alleviating symptoms and signs of endometriosis .  LA depot recipients lost significantly more BMD , had more days with subjective hot flushes and more objective ly measured hot flushes than did nafarelin recipients . In the nafarelin group , estradiol levels were consistently higher than in the leuprolide depot group , with significant differences by month 3 of dosing . CONCLUSION Nafarelin and LA depot were equally effective despite higher estradiol levels in nafarelin recipients . Nafarelin-treated subjects lost less BMD , had fewer days with hot flushes and had fewer objective ly measured hot flushes
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .